NCT03506061CompletedPhase 2
Trikafta in Cystic Fibrosis Patients
iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations or N1303K CFTR
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trikafta for approximately four weeks. The study researchers will monitor clinical endpoints that include forced expiratory volume (FEV1) and sweat chloride. Additionally, the researchers will obtain skin biopsy material and/or blood sample from each subject so that induced pluripotent stem (iPS) cells can be modified into airway cell monolayers and tested for response to Trikafta. In this way, the study will evaluate an emerging and readily accessible in vitro endpoint as a predictor of clinical response. This study will serve as a pilot/test case for other clinical protocols relevant to patients with rare CFTR variants who do not currently receive modulator therapies.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 13 Apr 2018
- Start date
- 4 Sept 2019
- Primary completion date
- 13 Feb 2024
- Lead sponsor
- Emory University
- Diseases
- Cystic fibrosis
- NCT number
- NCT03506061
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 42
- From 4 Sept 2019 to the primary completion date, 13 Feb 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease in the 4 weeks prior to screening
- Listed for lung or liver transplant at the time of screening
- Inhibitors or inducers of CYP3A4, including certain herbal medications and grapefruit/grapefruit juice, or other medicines known to negatively influence Trikafta administration
- Treatment with another investigational drug or other intervention within one month prior to enrollment, throughout the duration of study participation, and for an additional four weeks following final drug administration
- Evidence of cataract/lens opacity determined to be clinically significant by an ophthalmologist at or within 3 months prior to the Screening Visit
Other illness
- Documented history of drug or alcohol abuse within the last year
- History of solid organ transplant
- Active therapy for non-tuberculosis mycobacterial infection or any plan to initiate non-tuberculosis mycobacterial therapies during the study period
- Known allergy to Trikafta
- Any other condition that in the opinion of the lead investigators might confound results of the study or pose an additional risk from administering study drug
Lab values
- Cirrhosis or elevated liver transaminases \> 3 times the upper limit of normal
Other
- Pregnant or breastfeeding
- Treatment in the last 6 months with an approved CFTR modulator
Who the study is looking for
- Provision of signed and dated informed consent form or assent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female age ≥12
- A clinical diagnosis of CF or CFTR-related disease and either: 1) evidence for a partial function mutation not currently covered or likely to be covered for treatment with a CFTR modulator (Substudy 1), or 2) N1303K CFTR and a minimal function mutation (Substudy 2)
- Sweat Chloride \< 80 mmol/L and/or pancreatic sufficiency (no exogenous pancreatic enzyme supplement therapy) or carrying the N1303K CFTR variant
- Able to perform spirometry meeting American Thoracic Society (ATS) criteria for acceptability and repeatability
- Clinically stable in the past 4 weeks with no evidence of CF exacerbation (prior to screening and study Day 1)
- Willingness to use at least one form of acceptable birth control including abstinence or condom with spermicide. This will include birth control for at least one month prior to screening and agreement to use such a method during study participation for an additional four weeks after the last administration of study drug
- Ability to take Trikafta
- Agreement to adhere to all current medical therapies as designated by the CF care center physician
Age in the registry: 12 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Emory Children's Center Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| University of Alabama Cystic Fibrosis Research Center Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.